Clinical Research
BibTex RIS Cite

Astımda Sitokin Düzeyi ve Oksidan yükün prognoza etkisi

Year 2023, Volume: 2 Issue: 4, 182 - 188, 25.12.2023
https://doi.org/10.57221/izmirtip.1284847

Abstract

GİRİŞ ve AMAÇ: Bu çalışmanın amacı astım ve atak sırasındaki sitokin düzeylerini ve inflamatuar parametreleri değerlendirmektir.
YÖNTEM ve GEREÇLER: 30 astım ataklı, 41 stabil astımlı ve 42 sağlıklı kontrol çalışmaya alındı. Tüm olgularda hemogram, C Reaktif protein(CRP), eritrosit sedimentasyon hızı(ESH), eritrositlerde indirgenmiş GSH, plazmada MDA ve ELISA yöntemi ile serum sitokin (IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, TNF-α) düzeyleri Enzyme-Linked ImmunoSorbent Assay (ELİSA) yöntemi ile çalışıldı.
BULGULAR: Gruplar arasında beyaz küre, nötrofil sayısı ortalamaları karşılaştırıldığında anlamlı fark saptandı (p<0,001, p=0,004). Atak sırasında ölçülen beyaz küre ve nötrofil sayısı ortalamasının, atak sonrasında azaldığı saptandı (p=0,045, p>0,05). Gruplar arasında ve atak sırasındaki ve sonrasındaki lenfosit sayısı ortalamaları karşılaştırıldığında anlamlı fark saptanmadı (p>0,05). Gruplar arasında ESH ve CRP ortalamaları karşılaştırıldığında anlamlı fark saptandı (p=0,001, p=0,005). Atak sırasındaki ESH ve CRP ortalamasının atak sonrasında azaldığı saptandı (p=0,610, p=0,306).Gruplar arasında ortalama MDA ve GSH düzeyleri karşılaştırıldığında anlamlı fark saptanmadı (p=0,107, p=0,386). Atak sırasındaki ortalama MDA düzeyi atak sonrasında azalırken, GSH ortalaması atak sonrasında artmış saptandı (p>0,05). Gruplar arasında ortalama IL-4, IL-6, IL-10, TNF-α düzeyleri açısından anlamlı fark saptanırken (p<0,001), ortalama IL-1β, IL-5, IL-8, IL-13 düzeyleri açısından anlamlı fark saptanmadı (p>0,05).
TARTIŞMA ve SONUÇ: Çalışma sonuçlarımıza göre, astım atak sırasındaki inflamasyon belirteçleri (beyazküre, nötrofil, CRP, ESH), oksidan yük göstergesi (MDA) ve sitokinler (IL-1β, IL-4, IL-5, IL-10) atak tedavisi sonrasında azalmıştır. Bu sonuçlar astım atağında oksidan yükün ve sitokinlerin arttığını teyit etmektedir.

Supporting Institution

Pamukkale üniversitesi

Project Number

2007TPF010

Thanks

Pamukkale üniversitesi'ne desteklediği için teşekkür ederiz

References

  • 1.Yasaratne D, Idrose NS, Dharmage SC. Asthma in developing countries in the Asia-Pacific Region (APR). Respirology. 2023;28:992-1004.
  • 2.Shaw DE, Green RH, Bradding P. Asthma exacerbations: prevention is better than cure. Ther Clin Risk Manag. 2005;1:273-7.
  • 3.Cosentini R, Tarsia P, Canetta C, Graziadei G, Brambilla AM, Aliberti S, et al. Severe asthma exacerbation: role of acute chlamydophila pneumonia and mycoplasma pneumoniae infection. Respir Res. 200830;9:48.
  • 4.Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38:872-97.
  • 5.Miller AL, Lukacs NW. Chemokine receptors: understanding their role in asthmatic disease. Immunol Allergy Clin North Am. 2004;24:667-83.
  • 6.Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med. 2001;52:1-14.
  • 7.Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol Rev. 2004;84:731-65.
  • 8.Wood LG, Gibson PG, Garg ML. Biomarkers of lipid peroxidation, airway inflamation and asthma. Eur Respir J. 2003;21:177-86.
  • 9.Ceylan E, Aksoy N, Gencer M, Vural H, Keles H, Selek S. Evaluation of oxidative–antioxidative status and the l-arginine–nitric oxide pathway in asthmatic patients. Respir Med. 2005;99:871-6.
  • 10.Nadeem A, Chhabra SK, Masood A, Raj HG. Increased oxidative stres and altered levels of antioxidants in asthma. J Allergy Clin Immunol. 2003;111:72-8
  • 11.Serinken M, Dursunoglu N, Cimrin AH. Bir üniversite hastanesi acil servisine astım atak ile başvuran erişkin hastaların hastane maliyetleri. Tuberk Toraks. 2009;57:198-204.
  • 12. Message SD, Lasa-Stanza V, Mallia P, Parker HL, Zhu J, Kebadze T, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A. 2008;105:13562-7.
  • 13.Whitelaw WA. Asthma deaths. Chest. 1991;99:1507-10.
  • 14.Ciencewicki J, Trivedi S, Kleeberger SR. Oxidants and the pathogenesis of lung diseases. J Allergy Clin Immunol. 2008;122:456-68.
  • 15.Gumral N, Naziroglu M, Ongel K, Beydilli ED, Ozguner F, Sutcu R, et al. Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods. Cell Biochem Funct. 2009;27:276-83.
  • 16.Mihmanlı A, Güneylioğlu D, Özseker F, Arslan S, Özgel M, Akkaya E. Astımlı hastalarda serbest oksijen radikalleri ve antioksidanların aktiviteleri. Toraks Dergisi. 2003;4:264-8.
  • 17.Sackesen C, Ercan H, Dizdar E, Soyer O, Gumus P, Tosun BN, et al. A comprehensive evaluation of the enzymatic and nonenzymatic antioxidant systems in childhood asthma. J Allergy Clin Immunol. 2008;122:78-85.
  • 18.Thomas SS, Chhabra SK. A study on the serum levels of interleukin-1 beta in bronchial asthma. J Indian Med Assoc. 2003;101:282-6.
  • 19. Silvestri M, Bontempelli M, Giacomelli M, Malerba M, Rossi GA, Di Stefano A, et al. High serum levels of tumour necrosis factor alpha and interleukin 8 in severe asthma: markers of systemic inflamation? Clin Exp Allergy. 2006;36:1373-81.
  • 20.Subratty AH, Hooloman NK. Role of circulating inflamatory cytokines in patients during an acute attack of bronchial asthma. Indian J Chest Dis Allied Sci. 1998;40:17-21.
  • 21.Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, et al. Proinflamatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol. 2001;125:177-83.
  • 22.Gönlüer U. Astmada akut faz reaktanları. Uzmanlık Tezi. İzmir, Ege Üniversitesi Tıp Fakültesi; 2007.
  • 23.Stanciu LA, Roberts K, Papadopoulos NG, Cho SH, Holgate ST, Coyle AJ, et al. IL-4 increases type 2, but not type 1, cytokine production in CD8 T cells from mild atopic asthmatics. Respir Res. 20057;6:67.
  • 24.Kutukculer N, Ozdogru E, Demir E, Tanac R. Plasma interleukin-3 and interleukin-4 concentrations in Turkish asthmatic children. Arch Dis Child. 1995;73: 378-9.
  • 25.Sahid El-Radhi A, Hogg CL, Bungre JK, Bush A, Corrigan CJ. Effect of oral glucocorticoid treatment on serum inflamatory markers in acute asthma. Arch Dis Child. 2000;83:158-62.

Effect of Cytokine Level and Oxidant Load on Prognosis in Asthma

Year 2023, Volume: 2 Issue: 4, 182 - 188, 25.12.2023
https://doi.org/10.57221/izmirtip.1284847

Abstract

INTRODUCTION and PURPOSE: The aim of this study is to evaluate cytokine levels and inflammatory parameters during asthma and attacks.
METHODS and MATERIALS: 30 asthmatic patients, 41 stable asthmatic patients and 42 healthy controls were included in the study. In all cases, hemogram, C Reactive protein (CRP), erythrocyte sedimentation rate (ESH), reduced GSH in erythrocytes, MDA in plasma and serum cytokines (IL-1β, IL-4, IL-5, IL-6, IL-8) by ELISA method. , IL-10, IL-13, TNF-α) levels were studied with the Enzyme-Linked ImmunoSorbent Assay (ELISA) method.
RESULTS: A significant difference was found when the white blood cell and neutrophil count averages were compared between the groups (p<0.001, p=0.004). It was determined that the average white blood cell and neutrophil count measured during the attack decreased after the attack (p=0.045, p>0.05). When the average lymphocyte count was compared between the groups and during and after the attack, no significant difference was detected (p>0.05). When the ESR and CRP averages were compared between the groups, a significant difference was detected (p = 0.001, p = 0.005). It was determined that the mean ESH and CRP levels during the attack decreased after the attack (p=0.610, p=0.306). When the mean MDA and GSH levels were compared between the groups, no significant difference was detected (p=0.107, p=0.386). While the average MDA level during the attack decreased after the attack, the average GSH level was found to increase after the attack (p>0.05). While there was a significant difference between the groups in terms of mean IL-4, IL-6, IL-10, TNF-α levels (p<0.001), no significant difference was found in mean IL-1β, IL-5, IL-8, IL-13 levels. (p>0.05).
DISCUSSION AND CONCLUSION: According to our study results, inflammation markers (white blood cell, neutrophil, CRP, ESH), oxidant load indicator (MDA) and cytokines (IL-1β, IL-4, IL-5, IL-10) during an asthma attack were affected by the attack treatment. decreased afterwards. These results confirm that oxidant load and cytokines increase during an asthma attack.

Project Number

2007TPF010

References

  • 1.Yasaratne D, Idrose NS, Dharmage SC. Asthma in developing countries in the Asia-Pacific Region (APR). Respirology. 2023;28:992-1004.
  • 2.Shaw DE, Green RH, Bradding P. Asthma exacerbations: prevention is better than cure. Ther Clin Risk Manag. 2005;1:273-7.
  • 3.Cosentini R, Tarsia P, Canetta C, Graziadei G, Brambilla AM, Aliberti S, et al. Severe asthma exacerbation: role of acute chlamydophila pneumonia and mycoplasma pneumoniae infection. Respir Res. 200830;9:48.
  • 4.Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38:872-97.
  • 5.Miller AL, Lukacs NW. Chemokine receptors: understanding their role in asthmatic disease. Immunol Allergy Clin North Am. 2004;24:667-83.
  • 6.Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med. 2001;52:1-14.
  • 7.Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol Rev. 2004;84:731-65.
  • 8.Wood LG, Gibson PG, Garg ML. Biomarkers of lipid peroxidation, airway inflamation and asthma. Eur Respir J. 2003;21:177-86.
  • 9.Ceylan E, Aksoy N, Gencer M, Vural H, Keles H, Selek S. Evaluation of oxidative–antioxidative status and the l-arginine–nitric oxide pathway in asthmatic patients. Respir Med. 2005;99:871-6.
  • 10.Nadeem A, Chhabra SK, Masood A, Raj HG. Increased oxidative stres and altered levels of antioxidants in asthma. J Allergy Clin Immunol. 2003;111:72-8
  • 11.Serinken M, Dursunoglu N, Cimrin AH. Bir üniversite hastanesi acil servisine astım atak ile başvuran erişkin hastaların hastane maliyetleri. Tuberk Toraks. 2009;57:198-204.
  • 12. Message SD, Lasa-Stanza V, Mallia P, Parker HL, Zhu J, Kebadze T, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A. 2008;105:13562-7.
  • 13.Whitelaw WA. Asthma deaths. Chest. 1991;99:1507-10.
  • 14.Ciencewicki J, Trivedi S, Kleeberger SR. Oxidants and the pathogenesis of lung diseases. J Allergy Clin Immunol. 2008;122:456-68.
  • 15.Gumral N, Naziroglu M, Ongel K, Beydilli ED, Ozguner F, Sutcu R, et al. Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods. Cell Biochem Funct. 2009;27:276-83.
  • 16.Mihmanlı A, Güneylioğlu D, Özseker F, Arslan S, Özgel M, Akkaya E. Astımlı hastalarda serbest oksijen radikalleri ve antioksidanların aktiviteleri. Toraks Dergisi. 2003;4:264-8.
  • 17.Sackesen C, Ercan H, Dizdar E, Soyer O, Gumus P, Tosun BN, et al. A comprehensive evaluation of the enzymatic and nonenzymatic antioxidant systems in childhood asthma. J Allergy Clin Immunol. 2008;122:78-85.
  • 18.Thomas SS, Chhabra SK. A study on the serum levels of interleukin-1 beta in bronchial asthma. J Indian Med Assoc. 2003;101:282-6.
  • 19. Silvestri M, Bontempelli M, Giacomelli M, Malerba M, Rossi GA, Di Stefano A, et al. High serum levels of tumour necrosis factor alpha and interleukin 8 in severe asthma: markers of systemic inflamation? Clin Exp Allergy. 2006;36:1373-81.
  • 20.Subratty AH, Hooloman NK. Role of circulating inflamatory cytokines in patients during an acute attack of bronchial asthma. Indian J Chest Dis Allied Sci. 1998;40:17-21.
  • 21.Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, et al. Proinflamatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol. 2001;125:177-83.
  • 22.Gönlüer U. Astmada akut faz reaktanları. Uzmanlık Tezi. İzmir, Ege Üniversitesi Tıp Fakültesi; 2007.
  • 23.Stanciu LA, Roberts K, Papadopoulos NG, Cho SH, Holgate ST, Coyle AJ, et al. IL-4 increases type 2, but not type 1, cytokine production in CD8 T cells from mild atopic asthmatics. Respir Res. 20057;6:67.
  • 24.Kutukculer N, Ozdogru E, Demir E, Tanac R. Plasma interleukin-3 and interleukin-4 concentrations in Turkish asthmatic children. Arch Dis Child. 1995;73: 378-9.
  • 25.Sahid El-Radhi A, Hogg CL, Bungre JK, Bush A, Corrigan CJ. Effect of oral glucocorticoid treatment on serum inflamatory markers in acute asthma. Arch Dis Child. 2000;83:158-62.
There are 25 citations in total.

Details

Primary Language Turkish
Subjects Clinical Sciences
Journal Section Research Articles
Authors

Nihal Akdeniz Ünal 0000-0003-2746-9063

Fatma Evyapan This is me 0000-0002-2877-242X

Project Number 2007TPF010
Publication Date December 25, 2023
Submission Date April 18, 2023
Published in Issue Year 2023 Volume: 2 Issue: 4

Cite

APA Akdeniz Ünal, N., & Evyapan, F. (2023). Astımda Sitokin Düzeyi ve Oksidan yükün prognoza etkisi. İzmir Tıp Fakültesi Dergisi, 2(4), 182-188. https://doi.org/10.57221/izmirtip.1284847
AMA Akdeniz Ünal N, Evyapan F. Astımda Sitokin Düzeyi ve Oksidan yükün prognoza etkisi. İzmir Tıp Fak. Derg. December 2023;2(4):182-188. doi:10.57221/izmirtip.1284847
Chicago Akdeniz Ünal, Nihal, and Fatma Evyapan. “Astımda Sitokin Düzeyi Ve Oksidan yükün Prognoza Etkisi”. İzmir Tıp Fakültesi Dergisi 2, no. 4 (December 2023): 182-88. https://doi.org/10.57221/izmirtip.1284847.
EndNote Akdeniz Ünal N, Evyapan F (December 1, 2023) Astımda Sitokin Düzeyi ve Oksidan yükün prognoza etkisi. İzmir Tıp Fakültesi Dergisi 2 4 182–188.
IEEE N. Akdeniz Ünal and F. Evyapan, “Astımda Sitokin Düzeyi ve Oksidan yükün prognoza etkisi”, İzmir Tıp Fak. Derg., vol. 2, no. 4, pp. 182–188, 2023, doi: 10.57221/izmirtip.1284847.
ISNAD Akdeniz Ünal, Nihal - Evyapan, Fatma. “Astımda Sitokin Düzeyi Ve Oksidan yükün Prognoza Etkisi”. İzmir Tıp Fakültesi Dergisi 2/4 (December 2023), 182-188. https://doi.org/10.57221/izmirtip.1284847.
JAMA Akdeniz Ünal N, Evyapan F. Astımda Sitokin Düzeyi ve Oksidan yükün prognoza etkisi. İzmir Tıp Fak. Derg. 2023;2:182–188.
MLA Akdeniz Ünal, Nihal and Fatma Evyapan. “Astımda Sitokin Düzeyi Ve Oksidan yükün Prognoza Etkisi”. İzmir Tıp Fakültesi Dergisi, vol. 2, no. 4, 2023, pp. 182-8, doi:10.57221/izmirtip.1284847.
Vancouver Akdeniz Ünal N, Evyapan F. Astımda Sitokin Düzeyi ve Oksidan yükün prognoza etkisi. İzmir Tıp Fak. Derg. 2023;2(4):182-8.